ES2487493T3 - Formulaciones orales de glicil-2-metilprolil-glutamato - Google Patents

Formulaciones orales de glicil-2-metilprolil-glutamato Download PDF

Info

Publication number
ES2487493T3
ES2487493T3 ES07753175.4T ES07753175T ES2487493T3 ES 2487493 T3 ES2487493 T3 ES 2487493T3 ES 07753175 T ES07753175 T ES 07753175T ES 2487493 T3 ES2487493 T3 ES 2487493T3
Authority
ES
Spain
Prior art keywords
2mepe
composition
disease
composition according
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07753175.4T
Other languages
English (en)
Spanish (es)
Inventor
Jingyuan Wen
Gregory Brian Thomas
Mike John Bickerdike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUREN PHARMACEUTICALS Ltd
Neuren Pharmaceuticals Ltd New Zealand
Original Assignee
NEUREN PHARMACEUTICALS Ltd
Neuren Pharmaceuticals Ltd New Zealand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUREN PHARMACEUTICALS Ltd, Neuren Pharmaceuticals Ltd New Zealand filed Critical NEUREN PHARMACEUTICALS Ltd
Application granted granted Critical
Publication of ES2487493T3 publication Critical patent/ES2487493T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES07753175.4T 2006-03-14 2007-03-14 Formulaciones orales de glicil-2-metilprolil-glutamato Active ES2487493T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78214806P 2006-03-14 2006-03-14
US782148P 2006-03-14
PCT/US2007/006528 WO2007106555A2 (en) 2006-03-14 2007-03-14 Oral formulations of glycyl-2-methylprolyl-glutamate

Publications (1)

Publication Number Publication Date
ES2487493T3 true ES2487493T3 (es) 2014-08-21

Family

ID=38510089

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07753175.4T Active ES2487493T3 (es) 2006-03-14 2007-03-14 Formulaciones orales de glicil-2-metilprolil-glutamato

Country Status (5)

Country Link
US (3) US7887839B2 (https=)
EP (1) EP2001400B1 (https=)
JP (1) JP5220724B2 (https=)
ES (1) ES2487493T3 (https=)
WO (1) WO2007106555A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
EP2349209A2 (en) * 2008-09-26 2011-08-03 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
ES2386177B1 (es) * 2010-09-21 2013-09-23 Lipotec, S.A. Nanocapsulas conteniendo microemulsiones
AU2012209466C1 (en) 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CA2929286A1 (en) * 2012-11-28 2014-06-05 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
EP3024463B1 (en) * 2013-07-25 2020-03-25 Neuren Pharmaceuticals Limited Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
KR101695335B1 (ko) 2014-11-14 2017-01-11 한국기계연구원 코어-쉘 나노입자
KR20220059479A (ko) * 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물
BR102020010237A2 (pt) * 2020-05-22 2021-12-07 Ouro Fino Saúde Animal Ltda Plataforma para mascaramento de sabor
MX2023014655A (es) 2021-07-12 2024-01-12 Acadia Pharm Inc Formas cristalinas de trofinetida.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US7112570B2 (en) * 2000-08-24 2006-09-26 Neuren Pharmaceuticals, Ltd. GPE analogs
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
AUPR289601A0 (en) * 2001-02-05 2001-03-01 Commonwealth Scientific And Industrial Research Organisation Method of tissue repair
ATE435852T1 (de) * 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
GB0307428D0 (en) * 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
WO2005097161A2 (en) * 2004-03-30 2005-10-20 Neuren Pharmaceuticals Limited Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd Analogs of glycyl-prolyl-glutamate
WO2007106555A2 (en) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate

Also Published As

Publication number Publication date
US20090074865A1 (en) 2009-03-19
US7887839B2 (en) 2011-02-15
US8496963B2 (en) 2013-07-30
JP2009538269A (ja) 2009-11-05
US20110135730A1 (en) 2011-06-09
US20120277167A1 (en) 2012-11-01
EP2001400A2 (en) 2008-12-17
JP5220724B2 (ja) 2013-06-26
EP2001400B1 (en) 2014-05-07
WO2007106555A2 (en) 2007-09-20
WO2007106555A3 (en) 2008-10-30
US8178125B2 (en) 2012-05-15
EP2001400A4 (en) 2013-01-23

Similar Documents

Publication Publication Date Title
ES2487493T3 (es) Formulaciones orales de glicil-2-metilprolil-glutamato
JP6932389B2 (ja) 標的化コンジュゲートならびにその粒子及び製剤
Wang et al. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer
Biswas et al. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo
Fang et al. Pluronic P85-coated poly (butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy
Long et al. Azo-inserted responsive hybrid liposomes for hypoxia-specific drug delivery
CN102014870A (zh) 活性的一氧化氮供体及其制备和应用的方法
CN103370059A (zh) 一种药物递送装置
Xie et al. Retro-inverso bradykinin opens the door of blood–brain tumor barrier for nanocarriers in glioma treatment
Tripathy et al. Transdermal Delivery of Kidney-Targeting Nanoparticles Using Dissolvable Microneedles: Tripathy et al.
US20200114007A1 (en) Enhancement of the efficacy of therapeutic proteins
Dharap et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy
EP3650460A1 (en) Polypeptide pharmaceutically acceptable salt et use thereof
KR20170057148A (ko) 비강 투여를 통한 뇌졸중 치료용 조성물
Jia et al. Enhanced lymphatic transportation of SLN by mimicking oligopeptide transportation route
HK1243000A1 (zh) 用於增强PPARγ表现及核转位之化合物及其医疗用途
ES2869300T3 (es) Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
CN119818692B (zh) 一种负载麦角甾醇的脑靶向纳米制剂及其制备方法与应用
Yokosawa et al. Convection-enhanced delivery of a synthetic retinoid Am80, loaded into polymeric micelles, prolongs the survival of rats bearing intracranial glioblastoma xenografts
Hu et al. Study on the inhibitory effects of naringenin-loaded nanostructured lipid carriers against nonalcoholic fatty liver disease
US20240156742A1 (en) Targeted multifunctional nanostructured lipid carriers
CN107312071A (zh) 兴奋性神经毒性相关损伤的治疗方法
WO2020255574A1 (ja) 薬物送達用組成物および医薬組成物
RU2749481C1 (ru) Способ терапии поверхностных микозов
Hu et al. Modulation of endothelial-to-mesenchymal transition via NRP-1 targeting with melittin attenuates pulmonary fibrosis